Filing Scope and Business Context
The provided Form 10-Q is for Selecta Biosciences, Inc., not Cartesian Therapeutics, Inc. The filing covers the unaudited three and nine months ended September 30, 2020 and was signed November 5, 2020. Selecta is a clinical-stage biotechnology company developing its ImmTOR platform to reduce immunogenicity of biologic therapies and enable gene-therapy redosing. It had no approved products or product sales.
Financial Highlights
| Metric | Three months ended September 30, 2020 | Three months ended September 30, 2019 | Nine months ended September 30, 2020 | Nine months ended September 30, 2019 |
|---|---|---|---|---|
| Grant and collaboration revenue | $4.6 million | $0 | $4.6 million | $0.02 million |
| Research and development expense | $14.0 million | $8.1 million | $39.4 million | $27.6 million |
| General and administrative expense | $4.4 million | $3.7 million | $14.2 million | $12.3 million |
| Loss from operations | $(13.7) million | $(11.8) million | $(48.9) million | $(39.9) million |
| Net loss | $(9.7) million | $(12.0) million | $(53.4) million | $(40.5) million |
| Net loss per share | $(0.09) | $(0.26) | $(0.54) | $(0.94) |
| Net cash provided by operating activities | Not separately provided | Not separately provided | $42.1 million | $(38.6) million |
Reported revenue was entirely collaboration and grant revenue. Approximate net loss margins were negative 209% for the quarter and negative 1,150% for the nine-month period, reflecting the company’s early development stage and minimal revenue base.
Balance Sheet, Debt and Liquidity
- Cash and cash equivalents were $146.3 million at September 30, 2020, compared with $89.9 million at December 31, 2019. Cash, cash equivalents and restricted cash totaled $147.6 million.
- Management stated that available cash and restricted cash were expected to fund operating expenses and capital expenditures into the first quarter of 2023, subject to assumptions that may prove inaccurate.
- Total liabilities were $188.4 million and stockholders’ deficit was $7.4 million at September 30, 2020.
- Deferred revenue was $115.8 million, primarily associated with the Sobi license and other collaboration agreements; this is not yet recognized as revenue.
- The company recorded $24.6 million of non-current loan payable, reflecting the $25.0 million Term A Loan net of discounts and issuance costs. The $10.0 million Term B Loan remained subject to milestone conditions.
- Operating lease liabilities totaled $10.8 million, primarily related to the new eight-year headquarters lease.
Material Changes Versus the Prior Comparable Period
- Revenue increased to $4.6 million from $0.02 million for the nine-month period, primarily due to the Sobi and Sarepta arrangements.
- Nine-month research and development expense increased 43% to $39.4 million, driven mainly by the SEL-212 Phase 3 DISSOLVE program, the Phase 2 COMPARE trial and the AskBio collaboration.
- Nine-month net loss increased by $13.0 million to $53.4 million, despite lower loss per share because weighted-average shares increased substantially.
- Operating cash flow changed from $38.6 million of cash use to $42.1 million of cash provided, primarily because of $99.5 million in deferred-revenue collections under collaboration arrangements. This inflow is not indicative of recurring operating profitability.
- The company replaced its 2017 Term Loan with a new $25.0 million Term A Loan, repaying $13.7 million of prior debt and obtaining access to a potential additional $10.0 million Term B Loan.
- Common shares outstanding increased to 107.2 million from 86.3 million at year-end 2019, reflecting equity issuance and warrant exercises.
Guidance, Outlook, Risks and Unusual Items
- The Phase 3 DISSOLVE I and II trials for SEL-212 commenced in September 2020, with each trial expected to enroll 105 patients. Topline data was expected in the second half of 2022 and, if successful, a BLA filing was expected in the first quarter of 2023.
- The September 2020 COMPARE results showed a numerically higher response rate for SEL-212 on the primary endpoint but did not establish statistical superiority for the combined months 3 and 6 endpoint. Certain secondary analyses were statistically favorable. Full safety and efficacy analyses remained pending.
- Sobi licensed SEL-212 outside Greater China, paid a $75.0 million upfront fee and agreed to reimburse eligible Phase 3 development costs. The arrangement included potential milestone payments of up to $630.0 million and tiered royalties, but future milestone and royalty amounts remained uncertain.
- The company expects continuing operating losses and stated that it will require substantial additional financing. Potential future equity financing could dilute existing shareholders, while additional debt could increase fixed obligations and restrictive covenants.
- COVID-19 had not materially affected clinical programs as of the filing date, but management identified risks to patient enrollment, trial execution, supply chains, manufacturing and regulatory timelines.
- The new term loan is secured by substantially all assets other than intellectual property, while proceeds and licensing rights related to intellectual property are included in the collateral package. Defaults could permit acceleration of the debt.
- Common warrants were liability-classified and remeasured at fair value. The company recorded a $3.6 million loss for the nine-month period, offset by a $4.8 million gain in the third quarter as warrant fair value declined.
- A shareholder derivative lawsuit alleges fiduciary-duty breaches and corporate waste relating to the December 2019 private placement. Defendants filed a motion to dismiss; the filing does not provide a clear estimate of potential loss.
- Subsequent to quarter-end, the company entered into an option and license agreement with IGAN Biosciences and paid a $0.5 million upfront fee, according to the filing’s later-period discussion.
Most Important Facts for Investors to Verify
- Confirm the issuer identity: the supplied filing is Selecta Biosciences, Inc., whereas the request identifies Cartesian Therapeutics, Inc.
- Reconcile the $42.1 million of operating cash flow with the $99.5 million increase in deferred revenue and distinguish collected collaboration proceeds from recurring revenue.
- Review the Sobi license’s revenue-recognition assumptions, remaining performance obligations of $115.8 million and reimbursement terms for the DISSOLVE trials.
- Assess the statistical significance and complete safety dataset from the COMPARE trial, as the primary endpoint did not demonstrate statistical superiority on the combined endpoint.
- Evaluate liquidity beyond the stated first-quarter 2023 runway, including continuing losses, the conditional Term B Loan, potential equity dilution and warrant cash-repurchase provisions.
- Review the term-loan covenants, collateral package, milestone conditions and events of default.
- Monitor the shareholder derivative action and any developments concerning the December 2019 private placement.